Format

Send to

Choose Destination
OMICS. 2019 Dec;23(12):640-648. doi: 10.1089/omi.2019.0052. Epub 2019 Aug 8.

Glycomics for Type 2 Diabetes Biomarker Discovery: Promise of Immunoglobulin G Subclass-Specific Fragment Crystallizable N-glycosylation in the Uyghur Population.

Author information

1
Beijing Key Laboratory of Clinical Epidemiology, School of Public Health, Capital Medical University, Beijing, China.
2
College of the Life Sciences and Technology, Xinjiang University, Urumqi, China.
3
Genos Glycoscience Research Laboratory, Zagreb, Croatia.
4
School of Medical and Health Sciences, Edith Cowan University, Perth, Australia.
5
Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia.

Abstract

Aberrant immunoglobulin G (IgG) N-glycosylation offers new prospects to detect changes in cell metabolism and by extension, for biomarker discovery in type 2 diabetes mellitus (T2DM). However, past studies did not analyze the individual IgG subclasses in relation to T2DM pathophysiology. We report here original findings through a comparison of the IgG subclass-specific fragment crystallizable (Fc) glycan biosignatures in 115 T2DM patients with 122 healthy controls within the Uyghur population in China. IgG Fc glycosylation profiles were analyzed using nano-liquid chromatography-mass spectrometry to exclude changes attributed to fragment antigen binding N-glycosylation. After correction for clinical covariates, 27 directly measured and 4 derived glycan traits of the IgG subclass-specific N-glycopeptides were significantly associated with T2DM. Furthermore, we observed in T2DM a decrease in bisecting N-acetylglucosamine of IgG2 and agalactosylation of IgG4, and an increase in sialylation of IgG4 and digalactosylation of IgG2. Classification model based on IgG subclass-specific N-glycan traits was able to distinguish patients with T2DM from controls with an area under the receiver operating characteristic curve of 0.927 (95% confidence interval 0.894-0.960, p < 0.001). In conclusion, a robust association between the IgG subclass-specific Fc N-glycomes and T2DM was observed in the Uyghur population sample in China, suggesting a potential for the IgG Fc glycosylation as a biomarker candidate for type 2 diabetes. The integration of glycomics with other system science biomarkers might offer further hope for innovation in diagnosis and treatment of T2DM in the future. Finally, it is noteworthy that "Population Glycomics" is an emerging approach to biomarker discovery for common complex diseases.

KEYWORDS:

IgG; Uyghur population; biomarkers; glycomics; personalized medicine; subclass-specific Fc glycosylation; type 2 diabetes mellitus

PMID:
31393219
DOI:
10.1089/omi.2019.0052

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center